Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBITDA Margin (2023 - 2025)

Immunocore Holdings' EBITDA Margin history spans 3 years, with the latest figure at 26.93% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 443.0% year-over-year to 26.93%; the TTM value through Dec 2025 reached 7.46%, up 821.0%, while the annual FY2025 figure was 7.46%, 821.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 26.93% at Immunocore Holdings, down from 3.44% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 14.93% in Q3 2024 and bottomed at 33.39% in Q1 2024.
  • The 3-year median for EBITDA Margin is 15.65% (2023), against an average of 12.81%.
  • The largest annual shift saw EBITDA Margin plummeted -3055bps in 2024 before it skyrocketed 3945bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 0.82% in 2023, then crashed by -3747bps to 31.36% in 2024, then increased by 14bps to 26.93% in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EBITDA Margin are 26.93% (Q4 2025), 3.44% (Q3 2025), and 3.9% (Q2 2025).